Category - Markets

Markets

Roth starts Zafgen at buy; PT $8

Roth Capital Partners launched coverage of Zafgen (NASDAQ:ZFGN) with a “buy” rating and price target of $8. The stock closed at $2.56 on April 25.

April 26, 2019

Markets

SVB Leerink starts Genfit at OP; PT $58

SVB Leerink launched coverage of French-based Genfit (NASDAQ:GNFT) with an “outperform” rating and $58 price target. The stock closed at $25.47 on April 23.

April 24, 2019

Markets

Ladenburg starts Immunic at buy; PT $50

Ladenburg Thalmann initiated coverage of Immunic (NASDAQ:IMUX) with a “buy” rating and $50 price target. The stock closed at $14.30 on April 22.

April 23, 2019

Markets

BTIG starts Eidos Therapeutics at buy; PT $38

BTIG launched coverage of Eidos Therapeutics (NASDAQ:EIDX) with a “buy” rating and $38 price target. The stock closed at $23.38 on April 17.

April 18, 2019

Markets

BTIG starts Verona Pharma at buy; PT $17

BTIG initiated coverage of Verona Pharma (NASDAQ:VRNA) with a “buy” rating and a $17 price target. The stock closed at $6.13 on April 17.

April 18, 2019

Markets

Stifel starts Principia Biopharma at buy; PT $45

Stifel initiated coverage of Principia Biopharma (NASDAQ:PRNB) with a “buy” rating and $45 price target. The stock closed at $27.81 on April 15.

April 16, 2019

Markets

Paradigm starts Organigram at buy

Paradigm Capital launched coverage of Organigram Holdings (TSXV:OGI) with a “buy” rating. The stock closed at $9.40 on April 15.

April 16, 2019

Markets

Dyadic International approved for uplisting to NASDAQ

The common stock of Dyadic International (OTCQX:DYAI) was approved for listing on The Nasdaq Capital Market, beginning on April 17, under the trading symbol, DYAI. “Our listing on the NASDAQ is a major milestone...

April 15, 2019

Markets

SVB Leerink starts Tocagen at MP; PT $11

SVB Leerink initiated coverage of Tocagen (NASDAQ:TOCA) with a “market perform” rating and $11 price target. The stock closed at $10.26 on April 12. Tocagen is advancing a cancer-selective gene therapy platform that is...

April 15, 2019

Markets

Dawson James starts MYnd Analytics at buy; PT $4

Dawson James Securities initiated coverage of MYnd Analytics (NASDAQ:MYND) with a “buy” rating and price target of $4. The stock closed at $1.32 on April 11. Analyst Jason Kolbert writes that MYnd is working to bring...

April 12, 2019

Category - Markets

Roth starts Zafgen at buy; PT $8

SVB Leerink starts Genfit at OP; PT $58

Ladenburg starts Immunic at buy; PT $50

BTIG starts Eidos Therapeutics at buy; PT $38

BTIG starts Verona Pharma at buy; PT $17

Stifel starts Principia Biopharma at buy; PT $45

Paradigm starts Organigram at buy

Dyadic International approved for uplisting to NASDAQ

SVB Leerink starts Tocagen at MP; PT $11

Dawson James starts MYnd Analytics at buy; PT $4

General

More